Halozyme Therapeutics, Inc. $HALO Shares Sold by Shelton Wealth Management LLC

Shelton Wealth Management LLC decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 25.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,686 shares of the biopharmaceutical company’s stock after selling 5,371 shares during the period. Shelton Wealth Management LLC’s holdings in Halozyme Therapeutics were worth $1,732,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. MidFirst Bank bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics in the second quarter worth approximately $28,000. Quantbot Technologies LP bought a new stake in shares of Halozyme Therapeutics in the second quarter worth approximately $30,000. CoreCap Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 98.0% during the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 150 shares during the last quarter. Finally, Caitlin John LLC purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $44,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $83,995,132. The trade was a 2.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock valued at $13,538,046 in the last 90 days. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO traded up $0.33 on Friday, reaching $121.84. The company’s stock had a trading volume of 2,082,309 shares, compared to its average volume of 2,921,217. The stock’s 50 day simple moving average is $109.06 and its two-hundred day simple moving average is $84.92. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The stock has a market capitalization of $13.83 billion, a P/E ratio of 36.37, a PEG ratio of 0.46 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $122.45.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same period in the prior year, the company earned $1.54 earnings per share. The firm’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts forecast that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Zacks Research upgraded Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Finally, Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.55.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks upgraded HALO from “hold” to “strong buy,” citing strong price performance and favorable earnings trends. The upgrade helped reinforce investor momentum. 5 Stocks to Buy Using the Relative Price Strength Strategy
• Positive Sentiment: H.C. Wainwright reaffirmed its Buy rating on Halozyme, signaling continued confidence in the company’s growth outlook and commercial execution. H.C. Wainwright Reaffirms Their Buy Rating on Halozyme
• Positive Sentiment: TD Cowen projected substantial price appreciation for HALO, adding to the positive analyst sentiment surrounding the stock. TD Cowen Forecasts Strong Price Appreciation for Halozyme
• Positive Sentiment: Halozyme was highlighted in multiple stock-selection reports as a relative-strength and top-ranked nontechnology Nasdaq pick, based on strong price performance and rising earnings estimates. Buy 5 Top-Ranked Non-Tech Nasdaq Stocks
• Neutral Sentiment: An expanded agreement with argenx could improve Halozyme’s long-term royalty and licensing opportunity, but investors are weighing the deal’s ultimate financial contribution and execution risks. Is Expanded Argenx Deal Altering the Investment Case for Halozyme?

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.